MedTrace Logo

The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy

NCT03141125 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2017-08-29

No results posted yet for this study

Summary

Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017

Conditions

  • Scleroderma

Interventions

OTHER

Physalis angulata ethanol extract

Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months

OTHER

Placebo

No active component at the same dosage of 3x250 mg/day given orally for 3 months

Sponsors & Collaborators

  • Netherlands: Ministry of Health, Welfare and Sports

    collaborator OTHER_GOV

  • Indonesia University

    lead OTHER

Principal Investigators

  • Harry Isbagio, MD, Prof. · Department of Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03141125 on ClinicalTrials.gov